Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome

Ehud Rechtman, Valerie D. Allen, Ronald P. Danis, Linda M. Pratt, Alon Harris, Matthew A. Speicher

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

PURPOSE: To report the effects of intravitreal triamcinolone acetonide injections for subfoveal and juxtafoveal choroidal neovascularization (CNV) in ocular histoplasmosis syndrome. METHODS: In a retrospective analysis, the proportion of eyes that gained ≥5 or lost ≥5 and ≥15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, best-corrected visual acuity using ETDRS letter score (VA), greatest linear dimension (GLD), and treatment side effects were assessed. RESULTS: Ten patients (five subfoveal, five juxtafoveal CNV; median follow-up: 17 months; range, 6-41 months) were evaluated. Thirty percent gained ≥5 letters, 20% lost 5 to 14 letters, and 50% maintained stable VA. Overall, mean VA and GLD remained stable. Side effects were transient intraocular pressure elevation and mild cataract development. CONCLUSIONS: Intravitreal triamcinolone acetonide for CNV resulting from OHS was found to be relatively safe and showed good visual outcome for both subfoveal and juxtafoveal CNV. Further studies are warranted to evaluate this treatment.

Original languageEnglish
Pages (from-to)739-741
Number of pages3
JournalAmerican Journal of Ophthalmology
Volume136
Issue number4
DOIs
StatePublished - Oct 1 2003

Fingerprint

Triamcinolone
Histoplasmosis
Choroidal Neovascularization
Triamcinolone Acetonide
Diabetic Retinopathy
Therapeutics
Intraocular Pressure
Cataract
Visual Acuity
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. / Rechtman, Ehud; Allen, Valerie D.; Danis, Ronald P.; Pratt, Linda M.; Harris, Alon; Speicher, Matthew A.

In: American Journal of Ophthalmology, Vol. 136, No. 4, 01.10.2003, p. 739-741.

Research output: Contribution to journalArticle

Rechtman, Ehud ; Allen, Valerie D. ; Danis, Ronald P. ; Pratt, Linda M. ; Harris, Alon ; Speicher, Matthew A. / Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. In: American Journal of Ophthalmology. 2003 ; Vol. 136, No. 4. pp. 739-741.
@article{477ed75189274f0da81ed117c89d7eeb,
title = "Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome",
abstract = "PURPOSE: To report the effects of intravitreal triamcinolone acetonide injections for subfoveal and juxtafoveal choroidal neovascularization (CNV) in ocular histoplasmosis syndrome. METHODS: In a retrospective analysis, the proportion of eyes that gained ≥5 or lost ≥5 and ≥15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, best-corrected visual acuity using ETDRS letter score (VA), greatest linear dimension (GLD), and treatment side effects were assessed. RESULTS: Ten patients (five subfoveal, five juxtafoveal CNV; median follow-up: 17 months; range, 6-41 months) were evaluated. Thirty percent gained ≥5 letters, 20{\%} lost 5 to 14 letters, and 50{\%} maintained stable VA. Overall, mean VA and GLD remained stable. Side effects were transient intraocular pressure elevation and mild cataract development. CONCLUSIONS: Intravitreal triamcinolone acetonide for CNV resulting from OHS was found to be relatively safe and showed good visual outcome for both subfoveal and juxtafoveal CNV. Further studies are warranted to evaluate this treatment.",
author = "Ehud Rechtman and Allen, {Valerie D.} and Danis, {Ronald P.} and Pratt, {Linda M.} and Alon Harris and Speicher, {Matthew A.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0002-9394(03)00389-1",
language = "English",
volume = "136",
pages = "739--741",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome

AU - Rechtman, Ehud

AU - Allen, Valerie D.

AU - Danis, Ronald P.

AU - Pratt, Linda M.

AU - Harris, Alon

AU - Speicher, Matthew A.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - PURPOSE: To report the effects of intravitreal triamcinolone acetonide injections for subfoveal and juxtafoveal choroidal neovascularization (CNV) in ocular histoplasmosis syndrome. METHODS: In a retrospective analysis, the proportion of eyes that gained ≥5 or lost ≥5 and ≥15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, best-corrected visual acuity using ETDRS letter score (VA), greatest linear dimension (GLD), and treatment side effects were assessed. RESULTS: Ten patients (five subfoveal, five juxtafoveal CNV; median follow-up: 17 months; range, 6-41 months) were evaluated. Thirty percent gained ≥5 letters, 20% lost 5 to 14 letters, and 50% maintained stable VA. Overall, mean VA and GLD remained stable. Side effects were transient intraocular pressure elevation and mild cataract development. CONCLUSIONS: Intravitreal triamcinolone acetonide for CNV resulting from OHS was found to be relatively safe and showed good visual outcome for both subfoveal and juxtafoveal CNV. Further studies are warranted to evaluate this treatment.

AB - PURPOSE: To report the effects of intravitreal triamcinolone acetonide injections for subfoveal and juxtafoveal choroidal neovascularization (CNV) in ocular histoplasmosis syndrome. METHODS: In a retrospective analysis, the proportion of eyes that gained ≥5 or lost ≥5 and ≥15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, best-corrected visual acuity using ETDRS letter score (VA), greatest linear dimension (GLD), and treatment side effects were assessed. RESULTS: Ten patients (five subfoveal, five juxtafoveal CNV; median follow-up: 17 months; range, 6-41 months) were evaluated. Thirty percent gained ≥5 letters, 20% lost 5 to 14 letters, and 50% maintained stable VA. Overall, mean VA and GLD remained stable. Side effects were transient intraocular pressure elevation and mild cataract development. CONCLUSIONS: Intravitreal triamcinolone acetonide for CNV resulting from OHS was found to be relatively safe and showed good visual outcome for both subfoveal and juxtafoveal CNV. Further studies are warranted to evaluate this treatment.

UR - http://www.scopus.com/inward/record.url?scp=0141793688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141793688&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(03)00389-1

DO - 10.1016/S0002-9394(03)00389-1

M3 - Article

C2 - 14516819

AN - SCOPUS:0141793688

VL - 136

SP - 739

EP - 741

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -